Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00595426 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery
A Phase 2 study, sponsored by Astellas Pharma.
- Completed
- Registry status
- Phase 2
- Development phase
- 685
- Enrollment target
NCT00595426 is a Phase 2 study that has completed, run by Astellas Pharma. The registered enrollment target is 685 participants.
The verdict
NCT00595426, a Phase 2 study, has completed, sponsored by Astellas Pharma.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 685 participants
- Enrollment target
Study Summary
To evaluate the safety and efficacy of twice daily dosing and once daily dosing of YM150 in subjects undergoing primary elective knee replacement surgery
Interventions
- DRUG Warfarin
- DRUG YM150
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 685 participants |
| Start Date | 2008-05 |
| Est. Completion | 2009-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00595426
The ClinicalTrials.gov registry entry for NCT00595426 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 685 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astellas Pharma, which has 165 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Warfarin is the first listed.
NCT00595426 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00595426 about?
NCT00595426 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of YM150 in Patients With Knee Replacement Surgery". To evaluate the safety and efficacy of twice daily dosing and once daily dosing of YM150 in subjects undergoing primary elective knee replacement surgery
What is the current status of trial NCT00595426?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 685 participants. The study started on 2008-05. Estimated completion is 2009-05.
What interventions are being tested in trial NCT00595426?
The interventions under investigation include: Warfarin (DRUG), YM150 (DRUG).
Who is sponsoring clinical trial NCT00595426?
This trial is sponsored by Astellas Pharma, which has 165 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.